Skip to main content
IONIS PHARMACEUTICALS INC logo

IONIS PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · IONS ISIN · US4622221004 LEI · 549300SI4ZGLG0BLUZ92 US Manufacturing
Open in API
Filings indexed 1,796 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country US United States of America
Listing US IONS

About IONIS PHARMACEUTICALS INC

https://www.ionis.com/

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted therapeutics. Leveraging its expertise in antisense technology and a deep understanding of genetics, the company creates novel medicines designed to treat a wide range of serious diseases. Its development pipeline and marketed products primarily address neurologic and cardiometabolic disorders, as well as other areas with high unmet patient needs, including rare diseases. The company's approach aims to provide new solutions for complex and often intractable conditions by targeting the root cause of disease at the genetic level.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 87% confidence The document is a Current Report on Form 8-K filed with the SEC under Sections 7.01 (Regulation FD Disclosure) and 8.01 (Other Events). It furnishes a press release as Exhibit 99.1, discloses clinical trial data and forward-looking statements, and does not contain full financial statements or constitute an earnings release. It is a regulatory announcement rather than a standalone report (e.g., 10-K, IR) or other specific transaction. Therefore, it falls into the general Regulatory Filings category.
2026-05-28 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-04-30 English
10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-29 English
8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 29, 2026. It announces the company's financial results for the quarter ended March 31, 2026, and includes a press release as an exhibit. The text explicitly states that the report is a press release announcing quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document is about announcing initial quarterly financial results, not a full interim report with detailed financial statements, so it is not an Interim/Quarterly Report (IR). The length is 4069 characters, which is consistent with a press release rather than a full report. Therefore, the correct classification is Earnings Release (ER).
2026-04-29 English
ARS
Annual Report
2026-04-23 English
DEFA14A
Proxy Solicitation & Information Statement
2026-04-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.